Detalhe da pesquisa
1.
Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination.
Virol J
; 21(1): 70, 2024 03 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38515117